Form 4: Alkermes CMO Craig Hopkinson Executes Stock Option Plan

EVP and Chief Medical Officer Craig C. Hopkinson exercised options and sold 9,000 shares of Alkermes plc under a 10b5-1 plan.

Summary

• Craig C. Hopkinson, EVP R&D and Chief Medical Officer, exercised options for 5,000 ordinary shares at a price of $19.34.
• Following the exercise, a total of 9,000 shares were sold at a weighted average price of $41.6715 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2025.
• Post-transaction, the reporting person maintains beneficial ownership of 77,389 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was executed under a pre-established 10b5-1 plan and represents standard executive financial management.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information.
• The executive retains a significant equity stake of 77,389 shares in the company.

Negatives

• The transaction represents a net reduction in the executive's direct share ownership.

Risks

• Market volatility affecting the share price of Alkermes plc.
• Reliance on Rule 10b5-1 plans for liquidity, which may signal executive sentiment regarding future price appreciation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice for executives in the biopharmaceutical sector to manage personal liquidity and diversify portfolios, and generally does not reflect a change in corporate strategy.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice among S&P 500 and mid-cap biotech executives to ensure compliance with SEC insider trading regulations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was conducted via a pre-planned, automated trading mechanism.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Alkermes, ALKS, Insider Trading, Form 4, Biotech, Executive Compensation